[IMPORTANT: See Commentary Below]
A relatively unknown yet deadly cancer has become more common in the last few decades and is now the sixth most common cancer in the United States, according to the National Cancer Institute. This cancer of the immune system, known as Non-Hodgkin's lymphoma (NHL), became more familiar to the general public as it struck such luminaries as Jackie Kennedy Onassis, Senator Paul Tsongas, and the Shah Mohammed Reza Pahlevi of Iran.
NHL has increased 75 percent over the last 20 years, making it the most rapidly rising cancer after lung cancer and melanoma, NCI says. The incidence of NHL increased from 8.5 per 100,000 people in 1973 to 15.1 per 100,000 in 1991, and mortality from the disease increased from 4.8 per 100,000 people in 1973 to 6.5 per 100,000 in 1991 (illustrated in a 138K PDF file). Although recent studies have provided some intriguing clues, the cause of what some experts call the "NHL epidemic" is not known. Fortunately, advances in treatment seem to be keeping pace; the five-year survival rate for NHL rose from 31 percent to 51 percent over the past 30 years, according to NCI.
* http://www.fda.gov/fdac/graphics/1996graphics/nhlgraph.pdf
Cancers of the Immune System
NHL is a collection of more than a dozen different cancers of the lymphatic system, which generates the body's immune defenses. This system includes a network of channels akin to blood vessels through which lymphocytes—important white blood cells of the immune system—patrol the body for invading microbes. Along these lymphatic routes in the neck, armpits, abdomen, and groin are clusters of bean-shaped lymph nodes that house platoons of the infection-fighting lymphocytes. These cells also cluster in areas that serve as gateways to the body, including the mucous membranes lining the respiratory and digestive tracts, and the skin. Lymphocytes travel in the bloodstream, as well. The lymphatic system also includes such organs as the spleen, thymus and tonsils.
Because NHL can develop wherever in the body lymphocytes can be found, the cancer can crop up nearly anywhere. Symptoms can vary widely, depending on the cancer site. The most common symptom is a noticeable, usually painless swelling of a lymph node. NHL in the digestive tract can cause nausea, vomiting, or abdominal pain; in the chest, shortness of breath or cough may develop. If the brain is involved, patients may have headaches, vision changes, or seizures. If the bone marrow is affected, lymphoma cells may crowd out red blood cell precursors, causing anemia. Reddened patches on the skin can occur when lymphoma cells there prompt localized inflammation.
Because NHL can foster a hyperactive immune response, it often causes symptoms that develop when the body is fighting an infection, such as fevers, night sweats, tiredness, and weight loss. Another NHL symptom is widespread itching, apparently triggered by immune cells' release of histamines, the same compounds that cause itchiness in allergic reactions.
NHLs can affect people of all ages, although the incidence of NHL increases with age. About half of all cases are in people aged 60 and older.
The treatments for NHL include drugs and radiation therapy regulated by the Food and Drug Administration.
Diverse Group of Cancers
To diagnose NHL, doctors remove a small sample of the tissue thought to be cancerous. This procedure, known as a biopsy, is usually done with a local anesthetic. A pathologist examines the tissue under a microscope to look for cancer cells. The appearance of these cells and the proteins on their surfaces helps the pathologist determine the type of NHL the cancer is. The various types have distinctive appearances, carry different prognoses (predicted outcomes), and have different treatments. Whereas one type may be extremely deadly, another may be highly curable.
NHLs are classed as low-, intermediate- and high-grade. This classification scheme accurately predicts the survival of untreated patients, but is not as reliable in predicting outcome after treatment. Low-grade lymphomas are slow-growing tumors, and some patients can survive for more than a decade without treatment. Although chemotherapy often can shrink low-grade lymphomas, the cancer usually recurs within five years. Recurrent tumors can also be treated with chemotherapy or radiation, but over time, low-grade NHLs tend to become more aggressive and less responsive to therapy. Consequently, these types of lymphomas are not cured with currently available treatment.
In contrast, intermediate-grade and high-grade lymphomas are fast-growing tumors that, without treatment, generally are fatal within a year or two of diagnosis. Chemotherapy may cure many types of these lymphomas.
Doctors determine the stage of the cancer according to the number and location of tumors. This information, which also affects prognosis, is obtained from a physical exam, blood tests, and x-rays, CAT-scans, or ultrasound scans of various organs and tissues. Biopsies of the bone marrow and lymph nodes often are necessary. Regardless of NHL type, patients have a better prognosis with appropriate therapy if they have:
Younger patients also usually fare better than older ones.
A number of studies have pinpointed the genetic flaws that characterize different types or subtypes of NHL. Experts predict that this information will soon foster a new classification scheme that more accurately predicts outcome.
Treatment Varies
Doctors tailor treatment of NHL to the type of tumor, the stage of the disease, and the patient's age and general health. Most patients receive chemotherapy, radiation therapy, or both.
Because low-grade lymphomas usually grow slowly and cause few symptoms but eventually become resistant to treatment, doctors may postpone treatment until the cancer shows signs of spreading, or causes systemic symptoms (such as fevers or weight loss), or until the tumors become excessively bulky or threaten vital organs such as the kidneys or lungs. NCI researchers and others have shown that delaying treatment does not adversely affect long-term survival and may actually improve patients' quality of life, as the treatments themselves can be debilitating. A substantial proportion of patients with low-grade NHL have spontaneous remissions, although these disease-free periods rarely last for long.
Chemotherapy for NHL usually involves several different drugs given at the same time. Some drugs, such as chlorambucil (marketed as Leukeran), are given by mouth; others, such as cyclophosphamide (marketed as Cytoxan), are injected into a vein or muscle. To treat disease that has spread to the brain, chemotherapy may be delivered to the fluid that surrounds the brain through a needle in the spine. Chemotherapy is usually given in cycles: a treatment period followed by a rest period, then another treatment period, and so on.
A frequently used chemotherapy regimen for NHL combines cyclophosphamide, doxorubicin hydrochloride (marketed as Adriamycin), vincristine (marketed as Oncovin), and the anti-inflammatory drug prednisone. Although used for about 20 years, recent studies suggest this regimen is as effective and has less serious side effects than some of the newer drug combinations, according to Alan Aisenberg, M.D., of Massachusetts General Hospital.
An experimental NHL chemotherapy compound is a drug called fludarabine. FDA approved this drug as Fludara in 1991 for treating a type of leukemia, and, according to NCI's Bruce Cheson, M.D., early studies suggest that more low-grade NHL patients go into complete remission when they are treated with fludarabine than when they are treated with standard drugs such as chlorambucil.
Chemotherapy kills off rapidly dividing cells. Although its prime targets are the rapidly reproducing cancer cells, it also kills healthy dividing cells such as blood cells and the cells lining the intestinal tract and hair follicles. As a result, its side effects can include anemia, an increased risk of infection, mouth sores or bleeding, hair loss, nausea, and vomiting. Some of these side effects can be countered with anti-nausea medication or injections of hormone-like compounds called growth factors that help the body quickly restore its lost blood cells.
Some of the chemotherapy drugs used to treat NHL, such as doxorubicin and mitoxantrone, can damage heart tissue, making some people with heart disorders unable to tolerate this treatment. These patients may be given alternative kinds of chemotherapy and radiation therapy. Radiation therapy alone may be the treatment of choice for some patients, especially those who have only a single, small tumor. Some types of NHL respond best to chemotherapy followed by radiation therapy.
Radiation therapy uses high-energy x-rays to damage cancer cells and stop their growth. Radiation therapy is directed to the areas of the body known to harbor cancer cells. As an extra precaution, radiation may be directed to a broader area, such as to all the lymph nodes in the region of a known cancerous site. The treatment is generally given on an outpatient basis.
Radiation therapy can cause fatigue and red or dry skin in the treated area. Radiation directed to the chest and neck can cause patients to have a dry, sore throat and some trouble swallowing. Patients may also have shortness of breath or a dry cough. Radiation therapy to the abdomen may cause nausea, vomiting or diarrhea. Some patients who receive radiation to the spine may also have tingling or numbness in their arms, legs and lower back.
The chemotherapy used to treat NHL can cause sterility as can radiation directed to the pelvis. NHL treatments may also make patients more susceptible to other cancers, including those of the lung, brain, kidney, bladder, skin, and blood.
Bone Marrow Transplants
NHL patients with a poor prognosis may be candidates for high-dose chemotherapy with or without radiation followed by a bone marrow transplant. The transplant is necessary to restore the blood cells killed by the intensive cancer therapy. Before therapy, a portion of the patient's bone marrow is usually extracted and may be treated in an attempt to purge any cancer cells. The bone marrow contains "stem" cells, which are immature cells from which all blood cells develop. The bone marrow is returned to the patient after therapy. Patients may also receive stem cells harvested and enriched from their blood. Growth factors to boost the production of blood cells are also used in conjunction with bone marrow transplants.
Intensive radiation or chemotherapy followed by a bone marrow transplant has a number of potential serious side effects, including life-threatening infections, bleeding, damage to the liver, kidneys, lungs or heart, and subsequent leukemia. Although FDA has approved the chemotherapy drugs and growth factors most commonly used in conjunction with bone marrow transplants for cancer therapy, it does not regulate the procedure itself, just as it does not regulate other surgery and medical procedures considered "practice of medicine."
Studies provide strong evidence that bone marrow transplants improve the long-term survival of patients with intermediate- or high-grade lymphomas that have relapsed but are still sensitive to chemotherapy. There is little, if any, evidence of patients with low-grade lymphomas benefiting from the procedure, according to NCI's Cheson. Also, bone marrow transplants are usually not effective in NHL patients whose tumors do not respond to chemotherapy. NCI is supporting more research to assess the value of bone marrow treatment for different types of NHL.
Research is also under way to evaluate the safety and effectiveness of monoclonal antibody therapies in NHL patients. Monoclonal antibodies are synthetic antibodies that latch onto specific substances called antigens. Some antigens are unique to lymphoma cells. Researchers have designed monoclonal antibodies directed towards these lymphoma antigens. The antibodies may be attached to radioactive compounds or toxins that kill cells. Monoclonal antibody therapy is designed to more selectively target cancer cells, resulting in less severe side effects than standard therapy. Researchers are also testing the anti-cancer potential of a number of compounds produced by immune cells. These compounds, which include interleukin 2 and alpha interferon, are usually given in addition to standard chemotherapy or radiation therapies.
"We're at an exciting time in lymphoma research," said Cheson. "There are a lot of promising new drugs on the horizon." And people are eyeing that horizon more intently as NHL becomes more common.
Margie Patlak is a writer in Elkins Park, Pa.
Source: http://www.fda.gov/fdac/features/096_nhl.html 26jun2005
Reading this article one would think that some major miracle has happened and that "the cure" for NHL is just around the corner. The article states that "advances in treatment seem to be keeping pace."
Taking a look at the graph directly above, we don't come to the same conclusion as the author. In fact, it looks like the so-called advances are retreating in comparison to the incidence at this time, and have been for the last 20 years.
What's most annoying to us is the compulsion of the cancer industry to focus our attention on the "survival rate" rather than how many people are getting cancer. While most cancer survivors are grateful to be alive, one can be most certain that they would rather have not gotten it in the first place!
By focusing your attention on the survival rate rather than the incidence, you neglect to ask the simple question:
WHY did so many people get cancer?
Of course we need to help all those cancer patients to live. But they're deceiving you by making you think that there is a cure. The great search for The Cure is the most widely publicised medical research to date. Thousands of people work to bring in donations to find The Cure each day of the year. Like most of the healthcare industry, the American Cancer Society (ACS) is a nonprofit that takes donations from the very companies that produce and use the chemicals that cause cancers such as NHL. [See 2004 list of donors below]
Donors of more than $100,000 to the ACS include cosmetics companies (Christian Dior, Elizabeth Arden, Estee Lauder, Avon, Revlon), biotech companies (Amgen, Genentech), petrochemical companies (DuPont, BP, Pennzoil), auto companies (Nissan), industrial waste companies (BFI Waste Systems), junk food companies (Wendy’s International, Unilever/Bestfoods, Coca-Cola) and a slew of pharmaceutical companies (AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Merck & Company, Novartis).
And of its $800 million budget, the American Cancer Society spends an incredibly miniscule 1/10 of 1 percent — $800,000 — on prevention. Without reversing this spending policy and making prevention the $799.2 million piece of the pie, we are assured that cancer will be with us for decades to come. Additionally, by continuing this search for the cure by treating symptoms, the ACS and the rest of the cancer industry has insured its profits for decades to come.
Let's put most of our effort into prevention! We don't need the ACS or most of the cancer and healthcare industries for that. We each have the capability in our possession right now. It merely means educating yourself on what you should and should not eat; what you should not expose yourself and family to; exercising properly; not working too much; and finding people who will listen to you and love you. Stay away from all processed foods, commercial (nonorganic) agricultural fields, cosmetics, canned foods and beverages, and more.
Stop getting your news from television. In fact just stop watching it at all. After an initial cold-turkey period of getting unhooked, you'll be quite glad you id it and wonder why you ever did watch it.
Would you invite a criminal into your house for dinner and to teach your children about life? Of course not! But that is exactly what you do the moment that TV is turned on. By just turning on that TV, you might as well have taken the front door to your apartment or house off its hinges and put a rather large, colorful sign in front of your home asking criminals to come in.
Basically we need to practice healthy eating, exercising, sleeping, and working habits — live life mindfully!
This acknowledges those distinguished individuals who have cumulatively contributed $100,000 or more this year in support of the American Cancer Society. This list reflects contributions or pledges made from January 1, 2004 through December 31, 2004.
Noble Visionaries ($1,000,000+)
Distinguished Visionaries ($100,000 - $999,999)
source: http://www.cancer.org/docroot/AA/content/AA_1_7_American_Cancer_Society_Annual_Report_2004.asp 27jun2005
|
To
send us your comments, questions, and suggestions click
here |